Previous close | 10.60 |
Open | 10.59 |
Bid | 10.88 x 200 |
Ask | 10.94 x 400 |
Day's range | 10.55 - 10.92 |
52-week range | 6.92 - 16.65 |
Volume | |
Avg. volume | 135,900 |
Market cap | 198.386M |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.03 |
Earnings date | 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.17 |
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patie
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.